SAN DIEGO, Feb. 3, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at several high-profile events in February, including:
The 18th Annual BIO CEO & Investor Conference
Punit Dhillon, President and CEO, will present a corporate overview at The 18th Annual BIO CEO & Investor Conference on February 8 at 11:00 AM ET at The Waldorf Astoria in New York City. To view to the live webcast, please access the following link at the time of the presentation: http://www.veracast.com/webcasts/bio/ceoinvestor2016/76113125724.cfm. An archived version of the webcast will be available for 90 days on OncoSec's website: http://www.oncosec.com.
In its eighteenth year, The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Companies are able to present their company story to an audience of target investors and meet one-on-one with new and current investors, analysts, investment bankers, and other potential corporate partners. The conference also provides a platform to network with peers, investors, and potential partners attending the conference. For more information, please visit: https://www.bio.org/events/conferences/bio-ceo-investor-conference.
Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
Mr. Dhillon will present a corporate overview at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on February 10 at 12:30 PM ET at Convene in New York City.
The 2016 Disruptive Growth & Healthcare Conference will feature presentations from life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models. Attendees will include over 400 institutional investors, accredited investors, family offices, analysts, registered investment advisors, wealth managers, Source representatives, and their clients. The panels will cover a variety of topics, including regenerative medicine, immunotherapy, diagnostics, disruptive innovations, and business models. For more information, please visit: www.sourcecapitalconference.com.
Biocom's Global Life Science Partnering Conference
Mr. Dhillon will present a corporate overview at Biocom's Global Life Science Partnering Conference taking place February 24-25 at The Lodge at Torrey Pines in La Jolla, CA.
Biocom's 6th Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. The conference will include panel discussions on relevant topics with senior industry leaders, start-up company presentations, one-on-one meetings, and numerous networking opportunities. For more information, please visit: https://www.biocom.org.
4th Annual Sachs Cancer Bio Partnering & Investment Forum
Robert H. Pierce, MD, Chief Scientific Officer, will present a corporate overview at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum on February 24 at 2:40 PM ET at the New York Academy of Sciences in New York City.
The 4th Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical, and biotech to facilitate partnering and funding/investment. The conference will attract approximately 250 delegates and 30 company presentations by listed and private biotechnology companies seeking licensing and investment opportunities. The event provides a platform for one-on-one meetings and dedicated meeting facilities to make the event more productive. For more information, please visit: http://www.sachsforum.com/.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
OncoSec Medical Incorporated
SOURCE OncoSec Medical Incorporated